Toxicological Sciences 69, 244-257 (2002)
Copyright © 2002 by the Society of Toxicology
SAFETY EVALUATION |
Toxicity of Ammonium Perfluorooctanoate in Male Cynomolgus Monkeys after Oral Dosing for 6 Months
* 3M, St. Paul, Minnesota 55144;
University of Verona, Verona 37134, Italy;
University of Dundee, Dundee DD1 95Y, Scotland;
Ineos Chlor, Runcorn, Cheshire WA7 4JE, United Kingdom;
¶ Daikin, Osaka 566-8585, Japan;
Clariant, Sulzbach D-65840, Germany;
DuPont, Newark, Delaware 19714; and
Covance, Madison, Wisconsin 53704
Ammonium perfluorooctanoate (APFO) is a processing aid in the production of fluoropolymers that has been shown to have a long half-life in human blood. To understand the potential toxicological response of primates, groups of male cynomolgus monkeys were given daily po (capsule) doses of either 0, 3, 10, or 30 (reduced to 20) mg/kg/day for 26 weeks. Two monkeys from each of the control and 10 mg/kg/day dose groups were observed for 90 days after the last dose. Clinical observations, clinical chemistry, determination of key hormones, gross and microscopic pathology, cell proliferation, peroxisomal proliferation, bile-acid determination, and serum and liver perfluorooctanoate (PFOA) concentrations were monitored. Toxicity, including weight loss and reduced food consumption, was noted early in the study at the 30 mg/kg/day dose; therefore, the dose was reduced to 20 mg/kg/day. The same signs of toxicity developed in 3 monkeys at 20 mg/kg/day, after which treatment of these monkeys was discontinued. One 30/20 mg/kg/day monkey developed the signs of toxicity noted above and a possible dosing injury, and this monkey was sacrificed in extremis on Day 29. A 3 mg/kg/day dose-group monkey was sacrificed in extremis on Day 137 for reasons not clearly related to APFO treatment. Dose-dependent increases in liver weight as a result of mitochondrial proliferation occurred in all APFO-treated groups. Histopathologic evidence of liver injury was not observed at either 3 or 10 mg/kg/day. Evidence of liver damage was seen in the monkey sacrificed in moribund condition at the highest dose. Body weights were decreased at 30/20 mg/kg. PFOA concentrations in serum and liver were highly variable, were not linearly proportional to dose, and cleared to background levels within 90 days after the last dose. A no observable effect level was not established in this study, and the low dose of 3 mg/kg/day was considered the lowest observable effect level based on increased liver weight and uncertainty as to the etiology leading to the moribund sacrifice of one low-dose monkey on Day 137. Other than those noted above, there were no APFO-related macroscopic or microscopic changes, changes in clinical chemistry, hormones, or urinalysis, or hematological effects. In particular, effects that have been associated with the development of pancreatic and testicular toxicity in rats were not observed in this study.
Key Words: ammonium perfluorooctanoate; repeated-dose toxicity; cynomolgus monkey; health effects; hepatotoxicity; APFO.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C J Sakr, J M Symons, K H Kreckmann, and R C Leonard Ischaemic heart disease mortality study among workers with occupational exposure to ammonium perfluorooctanoate Occup. Environ. Med., October 1, 2009; 66(10): 699 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Swedenborg, J. Ruegg, S. Makela, and I. Pongratz Endocrine disruptive chemicals: mechanisms of action and involvement in metabolic disorders J. Mol. Endocrinol., July 1, 2009; 43(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-Y. Lin, P.-C. Chen, Y.-C. Lin, and L.-Y. Lin Association Among Serum Perfluoroalkyl Chemicals, Glucose Homeostasis, and Metabolic Syndrome in Adolescents and Adults Diabetes Care, April 1, 2009; 32(4): 702 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Loveless, D. Hoban, G. Sykes, S. R. Frame, and N. E. Everds Evaluation of the Immune System in Rats and Mice Administered Linear Ammonium Perfluorooctanoate Toxicol. Sci., September 1, 2008; 105(1): 86 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fei, J. K. McLaughlin, R. E. Tarone, and J. Olsen Fetal Growth Indicators and Perfluorinated Chemicals: A Study in the Danish National Birth Cohort Am. J. Epidemiol., July 1, 2008; 168(1): 66 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Wolf, T. Moore, B. D. Abbott, M. B. Rosen, K. P. Das, R. D. Zehr, A. B. Lindstrom, M. J. Strynar, and C. Lau Comparative Hepatic Effects of Perfluorooctanoic Acid and WY 14,643 in PPAR-{alpha} Knockout and Wild-type Mice Toxicol Pathol, June 1, 2008; 36(4): 632 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lau, K. Anitole, C. Hodes, D. Lai, A. Pfahles-Hutchens, and J. Seed Perfluoroalkyl Acids: A Review of Monitoring and Toxicological Findings Toxicol. Sci., October 1, 2007; 99(2): 366 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Henderson and M. A. Smith Perfluorooctanoic Acid and Perfluorononanoic Acid in Fetal and Neonatal Mice Following In Utero Exposure to 8-2 Fluorotelomer Alcohol Toxicol. Sci., February 1, 2007; 95(2): 452 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Butenhoff, G. L. Kennedy Jr, P. M. Hinderliter, P. H. Lieder, R. Jung, K. J. Hansen, G. S. Gorman, P. E. Noker, and P. J. Thomford Pharmacokinetics of Perfluorooctanoate in Cynomolgus Monkeys Toxicol. Sci., December 1, 2004; 82(2): 394 - 406. [Abstract] [Full Text] [PDF]
|
|